Gyre Therapeutics, Inc. GYRE
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -398.49% | -157.32% | -40.15% | 109.97% | -- |
| Total Depreciation and Amortization | 40.58% | 77.11% | 81.86% | 92.91% | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -128.34% | 26.46% | 41.74% | -96.56% | -- |
| Change in Net Operating Assets | 108.54% | 46.46% | -16.07% | -147.99% | -- |
| Cash from Operations | -67.89% | 21.21% | -134.88% | -329.51% | -- |
| Capital Expenditure | -15.39% | 39.94% | 45.18% | 77.47% | -- |
| Sale of Property, Plant, and Equipment | -84.21% | -90.06% | -92.52% | -63.49% | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 6,327.01% | 102.15% | 128.72% | 105.67% | -- |
| Cash from Investing | 782.52% | 89.72% | 119.72% | 100.42% | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -97.83% | 608.88% | 880.48% | 1,956.47% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 102.47% | -428.46% | -570.34% | -2,243.20% | -- |
| Cash from Financing | -96.96% | 651.40% | 959.56% | 529.96% | -- |
| Foreign Exchange rate Adjustments | 943.17% | 376.27% | 193.04% | -160.09% | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -140.87% | 202.41% | 182.49% | 268.17% | -- |